Terns Pharmaceuticals Inc (TERN) - News Archive

Navigating Growth: Terns Pharmaceuticals Strategic Inducement Grants for New Talent and LeadershipTerns Pharmaceuticals, Inc. (Nasdaq: TERN) has been making significant strides in reinforcing its workforce through strat...

In the dynamic landscape of biopharmaceuticals, where innovation and talent are pivotal to success, Terns Pharmaceuticals, Inc. (Nasdaq: TERN), located in Foster City, California, is making notable strides not only in i...

On February 3, 2025, Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical firm renowned for its innovative approach to treating serious conditions such as oncology and obesity, disclosed the aw...

In the fast-evolving world of biopharmaceuticals, companies continuously seek innovative strategies to attract top talent, and Terns Pharmaceuticals Inc. appears to be employing a robust approach. This article interpret...

In a significant development for Terns Pharmaceuticals, Inc. (Nasdaq: TERN), the company announced on October 7, 2024, the granting of an equity inducement award to a new employee under its 2022 Employment Inducement Aw...

nnTerns Pharmaceuticals Successfully Closes Public Offering, Raising Approximately $172.7 Million for Advancements in Oncology and Obesity TherapeuticsnnIn a noteworthy advancement for the biopharmaceutical landscape, T...

In an exciting development, Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company specializing in small-molecule product candidates for treating serious diseases, including oncology and...

The landscape of biopharmaceuticals is rapidly evolving, as innovative compounds and methodologies are emerging to address complex health challenges. Terns Pharmaceuticals is making significant strides with two of its k...

Equity Inducement Award Practices: A Case Study of Terns PharmaceuticalsIn the constantly evolving field of biopharmaceuticals, the development and retention of top-tier talent are critical for maintaining competitive e...

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO TransitionFOSTER CITY, Calif., July 29, 2024 - Terns Pharmaceuticals, a leading clinical-stage biopharmaceut...

Obesity is a global health crisis that affects millions of people worldwide, leading to a wide range of health complications, including diabetes, cardiovascular diseases, and even certain types of cancer. Developing eff...

: Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a company at the forefront of developing innovative small molecule therapeutics, has recently announced the grant of equity inducement awards to new employees under the 2022...

Terns Pharmaceuticals Undergoes Leadership Changes as it Navigates the Path to Addressing Serious DiseasesFOSTER CITY, Calif., May 08, 2024 - Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutica...

In a move to bolster its leadership team, Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the granting of an equity inducement award to Melita Sun Jung, the newly appointed Chief Busines...

Terns Pharmaceuticals, a leading biopharmaceutical company, recently released data from an ongoing Phase 1 pharmacokinetic study of their novel allosteric BCR-ABL inhibitor TERN-701. The study focused on adult healthy v...

Terns Pharmaceuticals, a prominent clinical-stage biopharmaceutical company dedicated to combatting severe diseases, including oncology and obesity, has successfully obtained Orphan Drug Designation from the U.S. Food a...

Terns Pharmaceuticals Grants Inducement Awards to New CEO Amy BurroughsIn a recent press release, Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases s...